Dave Ricks'un ücretlendirmesi Eli Lilly'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b

Tazminat ve Piyasa: Dave 'nin toplam tazminatı ($USD 26.57M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 12.63M ).

Tazminat ve Kazançlar: Dave 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Dave Ricks (56 yo)

8yrs

Görev süresi

US$26,565,732

Tazminat

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	8yrs	US$26.57m	0.067% $ 486.6m
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.6yrs	US$11.85m	0.021% $ 155.6m
Anat Hakim	Executive VP	4.9yrs	US$7.01m	0.0034% $ 24.5m
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 16.5m
Lucas Montarce	Executive VP & CFO	less than a year	Veri yok	0.0012% $ 8.9m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	12.2yrs	Veri yok	0.00080% $ 5.8m
Diogo Rau	EVP & Chief Information and Digital Officer	3.7yrs	US$5.10m	0.0012% $ 8.9m
Eric Dozier	Executive Vice President of Human Resources & Diversity	2.1yrs	Veri yok	0.00093% $ 6.7m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	17yrs	US$5.38m	Veri yok
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.4yrs	Veri yok	Veri yok
Anne White	EVP & President of Lilly Neuroscience	6.3yrs	Veri yok	0.0073% $ 52.7m
Ilya Yuffa	EVP & President of Lilly International	4.3yrs	Veri yok	0.0022% $ 15.9m

6.3yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: LLY 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	8yrs	US$26.57m	0.067% $ 486.6m
Gabrielle Greene-Sulzberger	Independent Director	4yrs	US$335.50k	Veri yok
Sidney Taurel	Chairman Emeritus	16yrs	US$13.06m	Veri yok
Jon Erik Fyrwald	Independent Director	19.2yrs	US$344.88k	0.000010% $ 72.4k
Ralph Alvarez	Independent Director	15.8yrs	US$336.00k	0.000080% $ 579.2k
William Kaelin	Independent Director	12.6yrs	US$349.15k	Veri yok
Mary Hedley	Independent Director	2.7yrs	US$319.00k	0.000040% $ 289.6k
Juan Luciano	Lead Independent Director	8.9yrs	US$373.00k	Veri yok
Jon Moeller	Director	less than a year	Veri yok	0.000010% $ 72.4k
Katherine Baicker	Independent Director	13.1yrs	US$336.00k	Veri yok
Jamere Jackson	Independent Director	8.3yrs	US$345.00k	Veri yok
Kimberly Johnson	Independent Director	3.9yrs	US$316.00k	Veri yok

8.6yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LLY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/30 04:21
Gün Sonu Hisse Fiyatı	2025/01/30 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Eli Lilly and Company 63 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Alistair Campbell	Berenberg

Eli Lilly Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Recent updates

Eli Lilly Stock's Correction Brings Opportunity

Eli Lilly: Market Overreacted

Eli Lilly and Company Provides Earnings Guidance for the Fourth Quarter of 2024; Provides Earnings Guidance for the Year 2025

FDA Approves Lilly's Omvoh (Mirikizumab-Mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50

Eli Lilly and Company to Report Q4, 2024 Results on Feb 06, 2025

Eli Lilly and Company (NYSE:LLY) entered into an agreement to acquire Scorpion Therapeutics, Inc. for $2.5 billion

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Eli Lilly (NYSE:LLY) Will Pay A Larger Dividend Than Last Year At $1.50

U.S. Food and Drug Administration Approves Eli Lilly and Company's Zepbound (Tirzepatide) as the First and Only Prescription Medicine for Moderate-To-Severe Sleep Apnea in Adults with Obesity

Eli Lilly and Company's Kisunla™ (donanemab-azbt) Approves in China for the Treatment of Early Symptomatic Alzheimer's Disease

Eli Lilly: A Rare Buying Opportunity

Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.50

Eli Lilly and Company's Omvoh Recommends by CHMP for Approval in the European Union for Adults with Moderate to Severely Active Crohn's Disease

Dividend of US$1.50 announced

Eli Lilly and Company Announces Results from the Phase 3 Ember-3 Study of Imlunestrant

Eli Lilly and Company (NYSE:LLY) announces an Equity Buyback for $15,000 million worth of its shares.

Insufficient new directors

Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy

Eli Lilly and Company Announces Topline Results from the SURMOUNT-5 Phase 3B Open-Label Randomized Clinical Trial

Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly

Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Announces Positive Phase 2 Results for muvalaplin

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Third quarter dividend of US$1.30 announced

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges

Eli Lilly and Company Announces Positive Results from the TRAILBLAZER-ALZ 6 Phase 3B Study

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly Buy On Weakness Signal (Technical Analysis)

Consensus EPS estimates fall by 18%

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları